Post-Patent GLP-1s: A Win for Access or a Blow to Safety?
Patent protection for semaglutide is set to expire in several major markets. For liraglutide, that has already happened. The change could make some of the most successful obesity and diabetes drugs of recent years far more affordable for millions of patients. In Europe, however, it may still take years before generics reach the market and prices fall. The shift also poses potential […]
Post-Patent GLP-1s: A Win for Access or a Blow to Safety? Read More »
